COMPANYTeam

CEO

Kimihiko Sato

Kimihiko Sato obtained his master’s degree in molecular biology at the University of Tokyo. He started his career at Mitsui Sumitomo Insurance Company, in the product development department working on actuarial science.
He then worked as a management consultant at Boston Consulting Group for seven years, specific to the healthcare industry. Managing a team as a Project Leader, he developed and implemented a broad range of strategies such as mid/long-term corporate growth, new product launch, sales, and manufacturing for global and Japanese pharmaceutical companies.
He joined bitBiome Inc. in February 2020 and took on his current role in March 2021.

Founder/Director, CSO (Chief Scientific Officer)

Masahito Hosokawa, Ph.D.

Masahito Hosokawa received his Ph.D. in Engineering from Tokyo University of Agriculture and Technology in 2010.
After postdoctoral training at Shizuoka Cancer Center between 2011 and 2013, he moved to Waseda University in 2013 and started single-cell research as a JST-PRESTO researcher in 2015.
His research focuses on developing and applying novel microfluidic tools for single-cell genomics and transcriptomics. He founded bitBiome Inc. in 2018 based on his single-cell genomics platform. He has received major awards including The Young Scientists’ Prize by the Minister of Education, Culture, Sports, Science and Technology (2019) and the JST PRESTO Innovation Award (2019).
He also works as an associate professor at Waseda University.

External Director

Atsushi Usami, Ph.D.

Atsushi Usami studied pharmacology and neuroscience and received his Ph.D. in pharmaceutical sciences from the University of Tokyo and is a pharmacist. He worked as a consultant at MRI before joining UTEC in October 2013.
He focuses on seed/early-stage life science investments. He currently serves on the boards of Repertoire Genesis Inc., Goryo Chemical Inc., EditForce Inc., MiRTel Co. Ltd., Epigeneron Inc., Bugworks Research Inc., and OriCiro Genomics, Inc. He is a JST START promotor and a NEDO TCP mentor. He helps with commercialization and teaches seminar on industry-academia collaboration at colloquiums in the Graduate Program for Leader in Life Innovation at the University of Tokyo. He provides support for Life Science Innovation network Japan (LINK-J).

Auditor

Noriaki Sakamoto

Noriaki Sakamoto graduated from the Faculty of Economy from the University of Tokyo and entered METI. He left METI in 2008 and was appointed vice president of a logistics company. He earned MBA from Columbia University. He was an engagement manager at McKinsey & Company and then joined UTEC in August 2014.
He currently serves on the boards of Finatext Inc., Institution for a Global Society Corp., Retrieva, Inc., Neural Pocket Inc., JDSC Co., Liquid, Inc., and TRICOG HEALTH PTE. LTD. He has served as a corporate auditor of the Autonomous Control Systems Research Institute, Inc. / ACSL (listed on TSE Mothers in December 2018: 6232).

COO

Yuji Suzuki

Yuji Suzuki joined bitBiome in October 2021. He has an extensive experience in strategy, business development and operational transformation.
Previously he served as executive vice president in Human Metabolome Technologies and engagement manager in McKinsey & Company, leading and advising growth companies. He has also held senior positions at Rakuten Group, Inc. and Macromill, Bain Capital portfolio company.
He holds an MPhil in Oriental Studies from the University of Cambridge and a BA in International Relations from the University of Tokyo.

Head of R&D

Soichiro Tsuda, Ph.D.

Soichiro Tsuda obtained his PhD in Biology at Kobe University in 2007.
He worked as a Lord Kelvin-Adam Smith Research Fellow at the University of Glasgow, UK (2012), a JSPS Research Fellow (2019), and the Director of Application Development at On-Chip Biotechnologies, Co. Ltd. before joining bitBiome in October 2020. He has epertise in interdisciplinary research across biology, engineering, and mathematical modelling during his nearly 10 years of overseas research activities. At bitBiome, he is leading its new business development using microbial single cell genome analysis technology.